UCB

UCB (EBR:UCB) * FAST 4WARD showed monotherapy Cimzia® 400 mg, dosed every four weeks, provided significant and effective clinical benefits compared to placebo

UCB (EBR:UCB) Brussels, Belgium, October 31, 2008 at 6:00 PM (CET) - press release, regulated information:

UCB (EBR:UCB) Brussels, Belgium, October 31, 2008 at 6:00 PM (CET) - press release, regulated information:

UCB (EBR:UCB) Brussels, Belgium, October 31, 2008 at 6:00 PM (CET) - press release, regulated information:

UCB (EBR:UCB) UCB entitled to receive milestone payment and royalties from Pfizer

UCB (EBR:UCB) * UCB on track to achieve 2008 and 2009 financial outlook * Three new drug launches in nine months * Continued roll-out of strategy * Early research with two new external partnerships

UCB (EBR:UCB) Patients treated with Cimzia®, together with methotrexate (MTX), experienced a rapid and clinically significant improvement in physical function, pain and fatigue as early as week one.

UCB (EBR:UCB) * New antiepileptic drug with a novel mechanism of action * Vimpat® helped people with epilepsy who still had uncontrolled partial onset seizures with current treatment * Vimpat® will be available in the U.S. as oral tablets and intravenous (IV) infusion * Vimpat® should be launched in the U.S. early 2009 by the well-established UCB epilepsy team

UCB (EBR:UCB) Brussels, BELGIUM, September 25, 2008 at 06:00 pm CET - press release, regulated information: UCB announced today that it is withdrawing the European Marketing Authorisation Application with the European Medicines Agency (EMEA) for Vimpat® (lacosamide) in the treatment of diabetic neuropathic pain.

UCB (EBR:UCB) * Mark McDade appointed Executive Vice President Global Operations succeeding Bill Robinson, to retire